|
1. Wang F, Wang S, Zhang Z, Lin Q, Liu Y, Xiao Y, et al. Activation of NLRP3 inflammasome in the ovaries during the development and treatment of polycystic ovary syndrome. Int J Clin Exp Pathol. 2017;10:5022-30. 2. Barbagallo F, Pedrielli G, Bosoni D, Tiranini L, Cucinella L, Calogero A, et al. Sexual functioning in women with functional hypothalamic amenorrhea: Exploring the relevance of an underlying polycystic ovary syndrome (PCOS)-phenotype. J Endocrinol Invest. 2023;46:1623-32. doi: 10.1007/s40618-023-02021-7. 3. Yang J, Chen C. Hormonal changes in PCOS. J Endocrinol. 2024;261. doi: 10.1530/JOE-23-0342. 4. 4. Zeber-Lubecka N, Ciebiera M, Hennig EE. Polycystic ovary syndrome and oxidative stress—from bench to bedside. Int J Mol Sci. 2023;24:14126. doi: 10.3390/ijms241814126. 5. Shahid M, Wajid M. Polycystic ovary syndrome in North America. Polycystic Ovary Syndrome: Elsevier; 2024. p. 229-36. doi:10.1016/b978-0-323-87932-3.00039-6. 6. Valerievna KV, Guiglia RA, Alioto M. Are women with PCOS more at risk for endometrial cancer? What approach for such patients? Acta Bio Medica: Atenei Parmensis. 2023;94. doi: 10.23750/abm.v94i2.14175. 7. Yu L, Sun J, Wang Q, Yu W, Wang A, Zhu S, et al. Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis. J Ovarian Res. 2023;16:22. doi: 10.1186/s13048-022-01084-z. 8. Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, et al. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023;189:S1-S16. doi: 10.1093/ejendo/lvad082. 9. Nualla-Ong A, Wongwananuruk T, Angsuwathana S, Techatraisak K, Rattanachaiyanont M, Tanmahasamut P, et al. Contraceptive Pills or Cyclic Progestin in Thai Women with Polycystic Ovary Syndrome: A 3-year Observational Study. JHSMR. 2023. doi:10.31584/jhsmr.2023920. 10. Kumari I. Evaluation of the effect of oral contraceptive pills (OCP) and metformin on metabolic and endocrine parameters in PCOS. Int J LifeSci.Biotechnol Pharma Res. 2024;13:475-8. doi:10.7860/jcdr/2022/56913.16915. 11. Arshad A, Rehman KU, Butt HI, Bashir S, Umar F, Yaseen Z, et al. Effect of Clomiphene Citrate on Fertility Hormones in Women with Polycystic Ovarian Syndrome. Int Health Rev. 2024;4:1-13. doi:10.32350/ihr.42.01. 12. Budreviciute A, Damiati S, Sabir DK, Onder K, Schuller-Goetzburg P, Plakys G, et al. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Front Public Health. 2020;8:574111. doi: 10.3389/fpubh.2020.574111. 13. Shah SZ, Karam JA, Zeb A, Ullah R, Shah A, Haq IU, et al. Movement is improvement: the therapeutic effects of exercise and general physical activity on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Ther 2021;12:707-32. doi: 10.1007/s13300-021-01005-1. 14. Mizgier M, Jarząbek-Bielecka G, Formanowicz D, Jodłowska-Siewert E, Mruczyk K, Cisek-Woźniak A, et al. Dietary and physical activity habits in adolescent girls with polycystic ovary syndrome (PCOS)-HAstudy. J Clin Med. 2021;10:3469. doi: 10.3390/jcm10163469. 15. Bonab SB, Parvaneh M. Effect of 12 weeks of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Sci Sports. 2023;38:565-73. doi: 10.1016/j.scispo.2022.11.001. 16. Traylor CS, Johnson JD, Kimmel MC, Manuck TA. Effects of psychological stress on adverse pregnancy outcomes and nonpharmacologic approaches for reduction: an expert review. Am J Obstet Gynecol MFM. 2020;2:100229. doi: 10.1016/j.ajogmf.2020.100229. 17. Ziaie T, Rahebi SM, Rafat F, Savadzadeh S. The prevalence of polycystic ovaries in infertility by laparoscopy. JHNM. 2013;23:38-44. 18. Zhuang J, Liu Y, Xu L, Liu X, Zhou L, Tang L, et al. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecol Obstet Invest. 2014;77:217-23. doi: 10.1159/000358485. 19. Gabrielli L, Aquino EM. Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reprod Biol Endocrinol. 2012;10:1-10. doi: 10.1186/1477-7827-10-96. 20. Lauritsen MP, Bentzen J, Pinborg A, Loft A, Forman J, Thuesen L, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. Hum Reprod. 2014;29:791-801. doi: 10.1093/humrep/det469. 21. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27:3067-73. doi: 10.1093/humrep/des232. 22. Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol. 2011;62:238-42. 23. Kumarapeli V, Seneviratne RdA, Wijeyaratne CN, Yapa R, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semiurban population in Sri Lanka. Am J Epidemiol. 2008;168:321-8. doi: 10.1093/aje/kwn137. 24. Ganie MA, Rashid A, Sahu D, Nisar S, Wani IA, Khan J. Prevalence of polycystic ovary syndrome (PCOS) among reproductive age women from Kashmir valley: A cross‐sectional study. Int J Gynaecol Obstet. 2020;149:231-6. doi: 10.1002/ijgo.13125. 25. Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28:2562-9. doi: 10.1093/humrep/det262. 26. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011;24:223-7. doi: 10.1016/j.jpag.2011.03.002. 27. Naz MSG, Tehrani FR, Majd HA, Ahmadi F, Ozgoli G, Fakari FR, et al. The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis. Int J Reprod Biomed. 2019;17:533. doi: 10.18502/ijrm.v17i8.4818. 28. Aldossary K, Alotaibi A, Alkhaldi K, Alharbi R. Prevalence of polycystic ovary syndrome and relationship with obesity/overweight: cross-sectional study in Saudi Arabia. J Adv Pharm Edu Res. 2020;10:186-90. 29. Azargoon A, Mirmohammadkhani M, Borjian S. The prevalence of polycystic ovarian syndrome, metabolic abnormalities and its association with obesity in adolescents: a cross-sectional study in an urban population in Iran. Acta Med Iran. 2020:388-93. doi: 10.18502/acta.v58i8.4589. 30. Joham AE, Boyle JA, Zoungas S, Teede HJ. Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity. Am J Hypertens. 2015;28:847-51. doi: 10.1093/ajh/hpu251. 31. Macut D, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, et al. Hypertension in polycystic ovary syndrome: novel insights. Curr Hypertens Rev. 2020;16:55-60. doi: 10.2174/1573402115666190531071422. 32. Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population. Front Endocrinol. 2022;13:892125. doi: 10.3389/fendo.2022.892125.
|
